PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Given Consensus Rating of “Moderate Buy” by Analysts

by · The Cerbat Gem

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Get Free Report) has been assigned an average rating of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $4.3333.

A number of brokerages have weighed in on PMVP. Weiss Ratings upgraded shares of PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of PMV Pharmaceuticals in a research report on Friday. LADENBURG THALM/SH SH began coverage on shares of PMV Pharmaceuticals in a research note on Wednesday, July 8th. They issued a “buy” rating and a $3.00 price target on the stock. Finally, Oppenheimer reduced their target price on shares of PMV Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th.

Check Out Our Latest Stock Analysis on PMV Pharmaceuticals

Institutional Investors Weigh In On PMV Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Cooper Haims Advisors LLC purchased a new stake in shares of PMV Pharmaceuticals in the 2nd quarter worth approximately $52,000. Susquehanna International Group LLP purchased a new stake in shares of PMV Pharmaceuticals in the 2nd quarter worth approximately $50,000. Stonepine Capital Management LLC purchased a new stake in PMV Pharmaceuticals during the second quarter valued at approximately $718,355. Bank of America Corp DE purchased a new stake in PMV Pharmaceuticals during the second quarter valued at approximately $322,000. Finally, ADAR1 Capital Management LLC purchased a new stake in PMV Pharmaceuticals during the second quarter valued at approximately $269,000. 90.20% of the stock is owned by hedge funds and other institutional investors.

PMV Pharmaceuticals Stock Up 6.0%

NASDAQ:PMVP traded up $0.08 during midday trading on Friday, hitting $1.32. The company had a trading volume of 252,108 shares, compared to its average volume of 479,905. The stock’s fifty day moving average price is $1.25 and its 200-day moving average price is $1.29. PMV Pharmaceuticals has a 52-week low of $1.02 and a 52-week high of $1.88. The company has a market capitalization of $70.30 million, a PE ratio of -0.93 and a beta of 1.37.

PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.05. As a group, research analysts forecast that PMV Pharmaceuticals will post -1.38 earnings per share for the current year.

PMV Pharmaceuticals Company Profile

(Get Free Report)

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.

Featured Articles